Form 4: Relay Therapeutics Director Granted Significant Stock Options

Relay Therapeutics, Inc. Director Kathiresan Sekar was granted 136,681 stock options with an exercise price of $3.36, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Summary

• Kathiresan Sekar, a Director of Relay Therapeutics, Inc. (RLAY), was granted 136,681 stock options.
• The options have an exercise price of $3.36 per share.
• The grant date for these options was June 6, 2025.
• The options vest in full on the earlier of (a) the first anniversary of the grant date (June 6, 2026) or (b) the date of the next annual meeting of stockholders following the grant date.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Kathiresan Sekar beneficially owns 136,681 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for the individual, aligning their interests with shareholders, and is a standard practice in corporate compensation, indicating stability in governance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The options provide a potential future upside for the director if the company's stock price appreciates above the exercise price.

Negatives

• The value of the options is contingent on the future performance of Relay Therapeutics' stock, introducing market risk.
• There is no immediate cash benefit to the director from this grant; value is realized only upon exercise and sale of shares.

Risks

• The value of the stock options is subject to the volatility of Relay Therapeutics' common stock price.
• If the stock price does not rise above the exercise price of $3.36, the options may expire worthless.
• Future market conditions and company performance could negatively impact the intrinsic value of these options.

Future Outlook

The grant of stock options to a director suggests an ongoing commitment to the company's long-term strategy and performance, as the value of these options is tied to future stock price appreciation.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract, retain, and incentivize talent. This aligns the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for director equity grants, aiming to ensure continued engagement and alignment.

Stakeholder Impact

• Shareholders: The grant of options to a director is intended to align the director's long-term interests with those of the shareholders, potentially leading to better governance and strategic decisions aimed at increasing share value.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The options will vest in full on the earlier of June 6, 2026, or the date of the next annual meeting of stockholders following the grant date.
• Upon vesting, the director will have the right to exercise these options to purchase common stock at the exercise price of $3.36 per share until the expiration date of June 5, 2035.

Key Dates

Keywords

Relay Therapeutics, RLAY, Stock Option, Form 4, Insider Transaction, Executive Compensation, Equity Grant, Director Compensation, Beneficial Ownership